Having a higher metabolic tumor volume (MTV) before starting therapy is associated with worse prognosis in patients with non-small cell lung cancer (NSCLC) who receive first-line treatment with pembrolizumab, according to research published in Cancers.

Higher MTV was associated with inferior progression-free survival (PFS) and overall survival (OS), researchers found. They also discovered that a higher bone marrow-to-liver ratio (BLR) was associated with poor prognosis.

For this study, the researchers retrospectively evaluated the clinical implications of quantitative biomarkers derived from pretreatment PET/CT scans in 85 patients who received first-line pembrolizumab alone (15 patients) or in combination with chemotherapy (70 patients).


Continue Reading

The biomarkers assessed included total MTV, BLR, maximum and mean standardized uptake value, total lesion glycolysis, and spleen-to-liver ratio.

At a median follow-up of 12 months, patients with a lower MTV had significantly longer PFS and OS, as well as a significantly higher disease control rate (DCR).

The median PFS was 10 months for patients with an MTV of 70 mL or less and 4 months for patients with an MTV greater than 70 mL (P =.001). The median OS was not reached and 10 months, respectively (P =.004). The DCR was 81% and 53%, respectively (P =.007).

Patients with a lower BLR had significantly better PFS and OS but not DCR. The median PFS was 8 months for patients with a BLR of 1.06 or less and 4 months for patients with a BLR greater than 1.06 (P =.034). The median OS was 19 months and 6 months, respectively (P =.005). The DCR was 71% and 61%, respectively (P =.317).

The researchers noted that patients with an MTV greater than 70 mL had better prognosis if their BLR was 1.06 or less.

These results suggest that PET/CT-derived biomarkers can aid therapeutic decision-making in patients with NSCLC receiving immune checkpoint inhibitors (ICIs), according to the researchers.

They added that these findings have implications for clinical practice and made the following recommendations:

  • PET/CT should be performed at baseline in all patients with advanced NSCLC receiving ICIs
  • Patients with a high MTV should receive chemotherapy and ICIs in combination rather than ICIs alone
  • Patients at risk for early progression, as identified by PET/CT-derived biomarkers, should be monitored more closely during initial therapy.

Reference

Lang D, Ritzberger L, Rambousek V, et al. First-line pembrolizumab mono- or combination therapy of non-small cell lung cancer: Baseline metabolic biomarkers predict outcomes. Cancers. Published online December 3, 2021. doi:10.3390/cancers13236096